Global Angiotensin II Receptor Blocker Market

Angiotensin II Receptor Blocker Comprehensive Study by Type (Azilsartan, Candesartan, Eprosartan, Irbesartan, Losartan, Olmesartan, Telmisartan, Valsartan), Application (Hypertension, Cardiovascular risks, Kidney failure in diabetes, Chronic kidney diseases), End Users (Hospitals, Clinics, Nursing Homes, Others) Players and Region - Global Market Outlook to 2027

Angiotensin II Receptor Blocker Market by XX Submarkets | Forecast Years 2022-2027  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
Angiotensin II Receptor Blocker Market Scope
Angiotensin II receptor blockers, also known as angiotensin II receptor antagonists, which are medications that block the action of angiotensin II by preventing angiotensin II from binding angiotensin II receptors on the muscles surrounding blood vessels. The Angiotensin II receptor blockers market has high growth prospects due to the maximum used for chronic kidney disease patients and reducing proteinuria. For instance, In U.S., 21% of the population with 6 to 19 years of age possesses a minimum of 1 abnormal cholesterol measure, consequently, the demand for blood pressure lowing drugs is on rise worldwide. So, the future for angiotensin II receptor blockers looks promising. Moreover, growth in vascular remodeling, cardiac safety and renal protection expected to fuel the growth of the Angiotensin II receptor blockers market during the forecasted period.

AttributesDetails
Study Period2017-2027
Base Year2021
High Growth MarketAsia Pacific
Largest MarketNorth America
UnitValue (USD Million)
Key Companies ProfiledDaichii Sankyo (Japan), Lupin (Germany), Novartis (Switzerland), Abbvie (United States), Takeda (Japan), AstraZeneca (United Kingdom) and Zydus Cadila (United Kingdom)
CAGR%


Global Angiotensin II Receptor Blocker is a consolidated market due to the presence of a few players. The players are focusing on investing more in R&D. Which will enhance their market presence. The companies are also planning strategic activities like partnerships, mergers, and acquisitions to help them sustain in the market and maintain their competitive edge. Research Analyst at AMA estimates that United States Players will contribute to the maximum growth of Global Angiotensin II Receptor Blocker market throughout the predicted period.

Daichii Sankyo (Japan), Lupin (Germany), Novartis (Switzerland), Abbvie (United States), Takeda (Japan), AstraZeneca (United Kingdom) and Zydus Cadila (United Kingdom) are some of the key players that are part of study coverage.

About Approach
The research aims to propose a patent-based approach in searching for potential technology partners as a supporting tool for enabling open innovation. The study also proposes a systematic searching process of technology partners as a preliminary step to select the emerging and key players that are involved in implementing market estimations. While patent analysis is employed to overcome the aforementioned data- and process-related limitations, as expenses occurred in that technology allows us to estimate the market size by evolving segments as target market from the total available market.

Segmentation Overview
The study have segmented the market of Global Angiotensin II Receptor Blocker market by Type , by Application (Hypertension, Cardiovascular risks, Kidney failure in diabetes and Chronic kidney diseases) and Region with country level break-up.

On the basis of geography, the market of Angiotensin II Receptor Blocker has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). North America region held largest market share in the year 2021. Europe on the other hand stood as second largest market due to the presence of key companies into the region and high technological advancement.

Market Leaders and their expansionary development strategies
In April 2022, Drug maker Lupin completed the acquisition of a portfolio of brands from Anglo-French Drugs & Industries Limited (AFDIL) and its associates. The acquisition will strengthen the company's India formulation business by adding a fast-growing portfolio of vitamins, minerals, supplements, and neurological products.
In June 2022, Global pharma major Lupin Limited (Lupin) announced that Lupin Diagnostics had launched its first Regional Reference Laboratory in Patna, Bihar. The new Regional Reference Laboratory at Patna has capabilities to conduct a broad spectrum of routine and specialized tests in the fields of molecular diagnostics, cytology, microbiology, serology, hematology, immunology, and routine biochemistry.
“According to U.S. Food and Drug Administration Regulations, it has posted a warning letter to Mylan Pharmaceuticals, Inc. in Chodavaram Village, Vizianagaram, Andhra Pradesh, India. Mylan manufactures valsartan active pharmaceutical ingredient (API) and has been one subject of an ongoing global investigation into nitrosamine impurities in angiotensin II receptor blockers (ARBs) such as valsartan, losartan and irbesartan.”

Angiotensin II Receptor Blocker Market Dynamics:
AttributesDetails
Trends Influencing Market
  • Increasing Demand at Asia-Pacific Regions
Key Restraints
  • High Cost Associated with Angiotensin II Receptor Blocker.
  • Increasing Commercial Availability Hamper the Patients
Challenges
  • Patents Expiry of Antihypertensive Drugs is Anticipated to Challenge the Market
  • Loss of Exclusivity Leading to Increased Generic Competition
Market Opportunities
  • Technological Advancements such as Advanced Healthcare Infrastructure and Diagnosis Process.
  • Upsurge Demand for Accurate Treatment Options


Key Target Audience
Angiotensin II Receptor Blocker Manufacturers, Angiotensin II Receptor Blocker Provider, End-Use Market Participants of Different Segments of Angiotensin II Receptor Blocker, Government and Research Organizations, R&D Institutions and Others

Report Objectives / Segmentation Covered

By Type
  • Azilsartan
  • Candesartan
  • Eprosartan
  • Irbesartan
  • Losartan
  • Olmesartan
  • Telmisartan
  • Valsartan
By Application
  • Hypertension
  • Cardiovascular risks
  • Kidney failure in diabetes
  • Chronic kidney diseases
By End Users
  • Hospitals
  • Clinics
  • Nursing Homes
  • Others

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. High Incidence of Target Diseases Such as Obesity, Diabetes and Others
      • 3.2.2. Customer Awareness Towards Health Consciousness.
    • 3.3. Market Challenges
      • 3.3.1. Patents Expiry of Antihypertensive Drugs is Anticipated to Challenge the Market
      • 3.3.2. Loss of Exclusivity Leading to Increased Generic Competition
    • 3.4. Market Trends
      • 3.4.1. Increasing Demand at Asia-Pacific Regions
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Angiotensin II Receptor Blocker, by Type, Application, End Users and Region (value and price ) (2016-2021)
    • 5.1. Introduction
    • 5.2. Global Angiotensin II Receptor Blocker (Value)
      • 5.2.1. Global Angiotensin II Receptor Blocker by: Type (Value)
        • 5.2.1.1. Azilsartan
        • 5.2.1.2. Candesartan
        • 5.2.1.3. Eprosartan
        • 5.2.1.4. Irbesartan
        • 5.2.1.5. Losartan
        • 5.2.1.6. Olmesartan
        • 5.2.1.7. Telmisartan
        • 5.2.1.8. Valsartan
      • 5.2.2. Global Angiotensin II Receptor Blocker by: Application (Value)
        • 5.2.2.1. Hypertension
        • 5.2.2.2. Cardiovascular risks
        • 5.2.2.3. Kidney failure in diabetes
        • 5.2.2.4. Chronic kidney diseases
      • 5.2.3. Global Angiotensin II Receptor Blocker by: End Users (Value)
        • 5.2.3.1. Hospitals
        • 5.2.3.2. Clinics
        • 5.2.3.3. Nursing Homes
        • 5.2.3.4. Others
      • 5.2.4. Global Angiotensin II Receptor Blocker Region
        • 5.2.4.1. South America
          • 5.2.4.1.1. Brazil
          • 5.2.4.1.2. Argentina
          • 5.2.4.1.3. Rest of South America
        • 5.2.4.2. Asia Pacific
          • 5.2.4.2.1. China
          • 5.2.4.2.2. Japan
          • 5.2.4.2.3. India
          • 5.2.4.2.4. South Korea
          • 5.2.4.2.5. Taiwan
          • 5.2.4.2.6. Australia
          • 5.2.4.2.7. Rest of Asia-Pacific
        • 5.2.4.3. Europe
          • 5.2.4.3.1. Germany
          • 5.2.4.3.2. France
          • 5.2.4.3.3. Italy
          • 5.2.4.3.4. United Kingdom
          • 5.2.4.3.5. Netherlands
          • 5.2.4.3.6. Rest of Europe
        • 5.2.4.4. MEA
          • 5.2.4.4.1. Middle East
          • 5.2.4.4.2. Africa
        • 5.2.4.5. North America
          • 5.2.4.5.1. United States
          • 5.2.4.5.2. Canada
          • 5.2.4.5.3. Mexico
    • 5.3. Global Angiotensin II Receptor Blocker (Price)
      • 5.3.1. Global Angiotensin II Receptor Blocker by: Type (Price)
  • 6. Angiotensin II Receptor Blocker: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
    • 6.2. Peer Group Analysis (2021)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Daichii Sankyo (Japan)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Lupin (Germany)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Novartis (Switzerland)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Abbvie (United States)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Takeda (Japan)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. AstraZeneca (United Kingdom)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Zydus Cadila (United Kingdom)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
  • 7. Global Angiotensin II Receptor Blocker Sale, by Type, Application, End Users and Region (value and price ) (2022-2027)
    • 7.1. Introduction
    • 7.2. Global Angiotensin II Receptor Blocker (Value)
      • 7.2.1. Global Angiotensin II Receptor Blocker by: Type (Value)
        • 7.2.1.1. Azilsartan
        • 7.2.1.2. Candesartan
        • 7.2.1.3. Eprosartan
        • 7.2.1.4. Irbesartan
        • 7.2.1.5. Losartan
        • 7.2.1.6. Olmesartan
        • 7.2.1.7. Telmisartan
        • 7.2.1.8. Valsartan
      • 7.2.2. Global Angiotensin II Receptor Blocker by: Application (Value)
        • 7.2.2.1. Hypertension
        • 7.2.2.2. Cardiovascular risks
        • 7.2.2.3. Kidney failure in diabetes
        • 7.2.2.4. Chronic kidney diseases
      • 7.2.3. Global Angiotensin II Receptor Blocker by: End Users (Value)
        • 7.2.3.1. Hospitals
        • 7.2.3.2. Clinics
        • 7.2.3.3. Nursing Homes
        • 7.2.3.4. Others
      • 7.2.4. Global Angiotensin II Receptor Blocker Region
        • 7.2.4.1. South America
          • 7.2.4.1.1. Brazil
          • 7.2.4.1.2. Argentina
          • 7.2.4.1.3. Rest of South America
        • 7.2.4.2. Asia Pacific
          • 7.2.4.2.1. China
          • 7.2.4.2.2. Japan
          • 7.2.4.2.3. India
          • 7.2.4.2.4. South Korea
          • 7.2.4.2.5. Taiwan
          • 7.2.4.2.6. Australia
          • 7.2.4.2.7. Rest of Asia-Pacific
        • 7.2.4.3. Europe
          • 7.2.4.3.1. Germany
          • 7.2.4.3.2. France
          • 7.2.4.3.3. Italy
          • 7.2.4.3.4. United Kingdom
          • 7.2.4.3.5. Netherlands
          • 7.2.4.3.6. Rest of Europe
        • 7.2.4.4. MEA
          • 7.2.4.4.1. Middle East
          • 7.2.4.4.2. Africa
        • 7.2.4.5. North America
          • 7.2.4.5.1. United States
          • 7.2.4.5.2. Canada
          • 7.2.4.5.3. Mexico
    • 7.3. Global Angiotensin II Receptor Blocker (Price)
      • 7.3.1. Global Angiotensin II Receptor Blocker by: Type (Price)
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Angiotensin II Receptor Blocker: by Type(USD Million)
  • Table 2. Angiotensin II Receptor Blocker Azilsartan , by Region USD Million (2016-2021)
  • Table 3. Angiotensin II Receptor Blocker Candesartan , by Region USD Million (2016-2021)
  • Table 4. Angiotensin II Receptor Blocker Eprosartan , by Region USD Million (2016-2021)
  • Table 5. Angiotensin II Receptor Blocker Irbesartan , by Region USD Million (2016-2021)
  • Table 6. Angiotensin II Receptor Blocker Losartan , by Region USD Million (2016-2021)
  • Table 7. Angiotensin II Receptor Blocker Olmesartan , by Region USD Million (2016-2021)
  • Table 8. Angiotensin II Receptor Blocker Telmisartan , by Region USD Million (2016-2021)
  • Table 9. Angiotensin II Receptor Blocker Valsartan , by Region USD Million (2016-2021)
  • Table 10. Angiotensin II Receptor Blocker: by Application(USD Million)
  • Table 11. Angiotensin II Receptor Blocker Hypertension , by Region USD Million (2016-2021)
  • Table 12. Angiotensin II Receptor Blocker Cardiovascular risks , by Region USD Million (2016-2021)
  • Table 13. Angiotensin II Receptor Blocker Kidney failure in diabetes , by Region USD Million (2016-2021)
  • Table 14. Angiotensin II Receptor Blocker Chronic kidney diseases , by Region USD Million (2016-2021)
  • Table 15. Angiotensin II Receptor Blocker: by End Users(USD Million)
  • Table 16. Angiotensin II Receptor Blocker Hospitals , by Region USD Million (2016-2021)
  • Table 17. Angiotensin II Receptor Blocker Clinics , by Region USD Million (2016-2021)
  • Table 18. Angiotensin II Receptor Blocker Nursing Homes , by Region USD Million (2016-2021)
  • Table 19. Angiotensin II Receptor Blocker Others , by Region USD Million (2016-2021)
  • Table 20. South America Angiotensin II Receptor Blocker, by Country USD Million (2016-2021)
  • Table 21. South America Angiotensin II Receptor Blocker, by Type USD Million (2016-2021)
  • Table 22. South America Angiotensin II Receptor Blocker, by Application USD Million (2016-2021)
  • Table 23. South America Angiotensin II Receptor Blocker, by End Users USD Million (2016-2021)
  • Table 24. Brazil Angiotensin II Receptor Blocker, by Type USD Million (2016-2021)
  • Table 25. Brazil Angiotensin II Receptor Blocker, by Application USD Million (2016-2021)
  • Table 26. Brazil Angiotensin II Receptor Blocker, by End Users USD Million (2016-2021)
  • Table 27. Argentina Angiotensin II Receptor Blocker, by Type USD Million (2016-2021)
  • Table 28. Argentina Angiotensin II Receptor Blocker, by Application USD Million (2016-2021)
  • Table 29. Argentina Angiotensin II Receptor Blocker, by End Users USD Million (2016-2021)
  • Table 30. Rest of South America Angiotensin II Receptor Blocker, by Type USD Million (2016-2021)
  • Table 31. Rest of South America Angiotensin II Receptor Blocker, by Application USD Million (2016-2021)
  • Table 32. Rest of South America Angiotensin II Receptor Blocker, by End Users USD Million (2016-2021)
  • Table 33. Asia Pacific Angiotensin II Receptor Blocker, by Country USD Million (2016-2021)
  • Table 34. Asia Pacific Angiotensin II Receptor Blocker, by Type USD Million (2016-2021)
  • Table 35. Asia Pacific Angiotensin II Receptor Blocker, by Application USD Million (2016-2021)
  • Table 36. Asia Pacific Angiotensin II Receptor Blocker, by End Users USD Million (2016-2021)
  • Table 37. China Angiotensin II Receptor Blocker, by Type USD Million (2016-2021)
  • Table 38. China Angiotensin II Receptor Blocker, by Application USD Million (2016-2021)
  • Table 39. China Angiotensin II Receptor Blocker, by End Users USD Million (2016-2021)
  • Table 40. Japan Angiotensin II Receptor Blocker, by Type USD Million (2016-2021)
  • Table 41. Japan Angiotensin II Receptor Blocker, by Application USD Million (2016-2021)
  • Table 42. Japan Angiotensin II Receptor Blocker, by End Users USD Million (2016-2021)
  • Table 43. India Angiotensin II Receptor Blocker, by Type USD Million (2016-2021)
  • Table 44. India Angiotensin II Receptor Blocker, by Application USD Million (2016-2021)
  • Table 45. India Angiotensin II Receptor Blocker, by End Users USD Million (2016-2021)
  • Table 46. South Korea Angiotensin II Receptor Blocker, by Type USD Million (2016-2021)
  • Table 47. South Korea Angiotensin II Receptor Blocker, by Application USD Million (2016-2021)
  • Table 48. South Korea Angiotensin II Receptor Blocker, by End Users USD Million (2016-2021)
  • Table 49. Taiwan Angiotensin II Receptor Blocker, by Type USD Million (2016-2021)
  • Table 50. Taiwan Angiotensin II Receptor Blocker, by Application USD Million (2016-2021)
  • Table 51. Taiwan Angiotensin II Receptor Blocker, by End Users USD Million (2016-2021)
  • Table 52. Australia Angiotensin II Receptor Blocker, by Type USD Million (2016-2021)
  • Table 53. Australia Angiotensin II Receptor Blocker, by Application USD Million (2016-2021)
  • Table 54. Australia Angiotensin II Receptor Blocker, by End Users USD Million (2016-2021)
  • Table 55. Rest of Asia-Pacific Angiotensin II Receptor Blocker, by Type USD Million (2016-2021)
  • Table 56. Rest of Asia-Pacific Angiotensin II Receptor Blocker, by Application USD Million (2016-2021)
  • Table 57. Rest of Asia-Pacific Angiotensin II Receptor Blocker, by End Users USD Million (2016-2021)
  • Table 58. Europe Angiotensin II Receptor Blocker, by Country USD Million (2016-2021)
  • Table 59. Europe Angiotensin II Receptor Blocker, by Type USD Million (2016-2021)
  • Table 60. Europe Angiotensin II Receptor Blocker, by Application USD Million (2016-2021)
  • Table 61. Europe Angiotensin II Receptor Blocker, by End Users USD Million (2016-2021)
  • Table 62. Germany Angiotensin II Receptor Blocker, by Type USD Million (2016-2021)
  • Table 63. Germany Angiotensin II Receptor Blocker, by Application USD Million (2016-2021)
  • Table 64. Germany Angiotensin II Receptor Blocker, by End Users USD Million (2016-2021)
  • Table 65. France Angiotensin II Receptor Blocker, by Type USD Million (2016-2021)
  • Table 66. France Angiotensin II Receptor Blocker, by Application USD Million (2016-2021)
  • Table 67. France Angiotensin II Receptor Blocker, by End Users USD Million (2016-2021)
  • Table 68. Italy Angiotensin II Receptor Blocker, by Type USD Million (2016-2021)
  • Table 69. Italy Angiotensin II Receptor Blocker, by Application USD Million (2016-2021)
  • Table 70. Italy Angiotensin II Receptor Blocker, by End Users USD Million (2016-2021)
  • Table 71. United Kingdom Angiotensin II Receptor Blocker, by Type USD Million (2016-2021)
  • Table 72. United Kingdom Angiotensin II Receptor Blocker, by Application USD Million (2016-2021)
  • Table 73. United Kingdom Angiotensin II Receptor Blocker, by End Users USD Million (2016-2021)
  • Table 74. Netherlands Angiotensin II Receptor Blocker, by Type USD Million (2016-2021)
  • Table 75. Netherlands Angiotensin II Receptor Blocker, by Application USD Million (2016-2021)
  • Table 76. Netherlands Angiotensin II Receptor Blocker, by End Users USD Million (2016-2021)
  • Table 77. Rest of Europe Angiotensin II Receptor Blocker, by Type USD Million (2016-2021)
  • Table 78. Rest of Europe Angiotensin II Receptor Blocker, by Application USD Million (2016-2021)
  • Table 79. Rest of Europe Angiotensin II Receptor Blocker, by End Users USD Million (2016-2021)
  • Table 80. MEA Angiotensin II Receptor Blocker, by Country USD Million (2016-2021)
  • Table 81. MEA Angiotensin II Receptor Blocker, by Type USD Million (2016-2021)
  • Table 82. MEA Angiotensin II Receptor Blocker, by Application USD Million (2016-2021)
  • Table 83. MEA Angiotensin II Receptor Blocker, by End Users USD Million (2016-2021)
  • Table 84. Middle East Angiotensin II Receptor Blocker, by Type USD Million (2016-2021)
  • Table 85. Middle East Angiotensin II Receptor Blocker, by Application USD Million (2016-2021)
  • Table 86. Middle East Angiotensin II Receptor Blocker, by End Users USD Million (2016-2021)
  • Table 87. Africa Angiotensin II Receptor Blocker, by Type USD Million (2016-2021)
  • Table 88. Africa Angiotensin II Receptor Blocker, by Application USD Million (2016-2021)
  • Table 89. Africa Angiotensin II Receptor Blocker, by End Users USD Million (2016-2021)
  • Table 90. North America Angiotensin II Receptor Blocker, by Country USD Million (2016-2021)
  • Table 91. North America Angiotensin II Receptor Blocker, by Type USD Million (2016-2021)
  • Table 92. North America Angiotensin II Receptor Blocker, by Application USD Million (2016-2021)
  • Table 93. North America Angiotensin II Receptor Blocker, by End Users USD Million (2016-2021)
  • Table 94. United States Angiotensin II Receptor Blocker, by Type USD Million (2016-2021)
  • Table 95. United States Angiotensin II Receptor Blocker, by Application USD Million (2016-2021)
  • Table 96. United States Angiotensin II Receptor Blocker, by End Users USD Million (2016-2021)
  • Table 97. Canada Angiotensin II Receptor Blocker, by Type USD Million (2016-2021)
  • Table 98. Canada Angiotensin II Receptor Blocker, by Application USD Million (2016-2021)
  • Table 99. Canada Angiotensin II Receptor Blocker, by End Users USD Million (2016-2021)
  • Table 100. Mexico Angiotensin II Receptor Blocker, by Type USD Million (2016-2021)
  • Table 101. Mexico Angiotensin II Receptor Blocker, by Application USD Million (2016-2021)
  • Table 102. Mexico Angiotensin II Receptor Blocker, by End Users USD Million (2016-2021)
  • Table 103. Angiotensin II Receptor Blocker: by Type(USD/Units)
  • Table 104. Company Basic Information, Sales Area and Its Competitors
  • Table 105. Company Basic Information, Sales Area and Its Competitors
  • Table 106. Company Basic Information, Sales Area and Its Competitors
  • Table 107. Company Basic Information, Sales Area and Its Competitors
  • Table 108. Company Basic Information, Sales Area and Its Competitors
  • Table 109. Company Basic Information, Sales Area and Its Competitors
  • Table 110. Company Basic Information, Sales Area and Its Competitors
  • Table 111. Angiotensin II Receptor Blocker: by Type(USD Million)
  • Table 112. Angiotensin II Receptor Blocker Azilsartan , by Region USD Million (2022-2027)
  • Table 113. Angiotensin II Receptor Blocker Candesartan , by Region USD Million (2022-2027)
  • Table 114. Angiotensin II Receptor Blocker Eprosartan , by Region USD Million (2022-2027)
  • Table 115. Angiotensin II Receptor Blocker Irbesartan , by Region USD Million (2022-2027)
  • Table 116. Angiotensin II Receptor Blocker Losartan , by Region USD Million (2022-2027)
  • Table 117. Angiotensin II Receptor Blocker Olmesartan , by Region USD Million (2022-2027)
  • Table 118. Angiotensin II Receptor Blocker Telmisartan , by Region USD Million (2022-2027)
  • Table 119. Angiotensin II Receptor Blocker Valsartan , by Region USD Million (2022-2027)
  • Table 120. Angiotensin II Receptor Blocker: by Application(USD Million)
  • Table 121. Angiotensin II Receptor Blocker Hypertension , by Region USD Million (2022-2027)
  • Table 122. Angiotensin II Receptor Blocker Cardiovascular risks , by Region USD Million (2022-2027)
  • Table 123. Angiotensin II Receptor Blocker Kidney failure in diabetes , by Region USD Million (2022-2027)
  • Table 124. Angiotensin II Receptor Blocker Chronic kidney diseases , by Region USD Million (2022-2027)
  • Table 125. Angiotensin II Receptor Blocker: by End Users(USD Million)
  • Table 126. Angiotensin II Receptor Blocker Hospitals , by Region USD Million (2022-2027)
  • Table 127. Angiotensin II Receptor Blocker Clinics , by Region USD Million (2022-2027)
  • Table 128. Angiotensin II Receptor Blocker Nursing Homes , by Region USD Million (2022-2027)
  • Table 129. Angiotensin II Receptor Blocker Others , by Region USD Million (2022-2027)
  • Table 130. South America Angiotensin II Receptor Blocker, by Country USD Million (2022-2027)
  • Table 131. South America Angiotensin II Receptor Blocker, by Type USD Million (2022-2027)
  • Table 132. South America Angiotensin II Receptor Blocker, by Application USD Million (2022-2027)
  • Table 133. South America Angiotensin II Receptor Blocker, by End Users USD Million (2022-2027)
  • Table 134. Brazil Angiotensin II Receptor Blocker, by Type USD Million (2022-2027)
  • Table 135. Brazil Angiotensin II Receptor Blocker, by Application USD Million (2022-2027)
  • Table 136. Brazil Angiotensin II Receptor Blocker, by End Users USD Million (2022-2027)
  • Table 137. Argentina Angiotensin II Receptor Blocker, by Type USD Million (2022-2027)
  • Table 138. Argentina Angiotensin II Receptor Blocker, by Application USD Million (2022-2027)
  • Table 139. Argentina Angiotensin II Receptor Blocker, by End Users USD Million (2022-2027)
  • Table 140. Rest of South America Angiotensin II Receptor Blocker, by Type USD Million (2022-2027)
  • Table 141. Rest of South America Angiotensin II Receptor Blocker, by Application USD Million (2022-2027)
  • Table 142. Rest of South America Angiotensin II Receptor Blocker, by End Users USD Million (2022-2027)
  • Table 143. Asia Pacific Angiotensin II Receptor Blocker, by Country USD Million (2022-2027)
  • Table 144. Asia Pacific Angiotensin II Receptor Blocker, by Type USD Million (2022-2027)
  • Table 145. Asia Pacific Angiotensin II Receptor Blocker, by Application USD Million (2022-2027)
  • Table 146. Asia Pacific Angiotensin II Receptor Blocker, by End Users USD Million (2022-2027)
  • Table 147. China Angiotensin II Receptor Blocker, by Type USD Million (2022-2027)
  • Table 148. China Angiotensin II Receptor Blocker, by Application USD Million (2022-2027)
  • Table 149. China Angiotensin II Receptor Blocker, by End Users USD Million (2022-2027)
  • Table 150. Japan Angiotensin II Receptor Blocker, by Type USD Million (2022-2027)
  • Table 151. Japan Angiotensin II Receptor Blocker, by Application USD Million (2022-2027)
  • Table 152. Japan Angiotensin II Receptor Blocker, by End Users USD Million (2022-2027)
  • Table 153. India Angiotensin II Receptor Blocker, by Type USD Million (2022-2027)
  • Table 154. India Angiotensin II Receptor Blocker, by Application USD Million (2022-2027)
  • Table 155. India Angiotensin II Receptor Blocker, by End Users USD Million (2022-2027)
  • Table 156. South Korea Angiotensin II Receptor Blocker, by Type USD Million (2022-2027)
  • Table 157. South Korea Angiotensin II Receptor Blocker, by Application USD Million (2022-2027)
  • Table 158. South Korea Angiotensin II Receptor Blocker, by End Users USD Million (2022-2027)
  • Table 159. Taiwan Angiotensin II Receptor Blocker, by Type USD Million (2022-2027)
  • Table 160. Taiwan Angiotensin II Receptor Blocker, by Application USD Million (2022-2027)
  • Table 161. Taiwan Angiotensin II Receptor Blocker, by End Users USD Million (2022-2027)
  • Table 162. Australia Angiotensin II Receptor Blocker, by Type USD Million (2022-2027)
  • Table 163. Australia Angiotensin II Receptor Blocker, by Application USD Million (2022-2027)
  • Table 164. Australia Angiotensin II Receptor Blocker, by End Users USD Million (2022-2027)
  • Table 165. Rest of Asia-Pacific Angiotensin II Receptor Blocker, by Type USD Million (2022-2027)
  • Table 166. Rest of Asia-Pacific Angiotensin II Receptor Blocker, by Application USD Million (2022-2027)
  • Table 167. Rest of Asia-Pacific Angiotensin II Receptor Blocker, by End Users USD Million (2022-2027)
  • Table 168. Europe Angiotensin II Receptor Blocker, by Country USD Million (2022-2027)
  • Table 169. Europe Angiotensin II Receptor Blocker, by Type USD Million (2022-2027)
  • Table 170. Europe Angiotensin II Receptor Blocker, by Application USD Million (2022-2027)
  • Table 171. Europe Angiotensin II Receptor Blocker, by End Users USD Million (2022-2027)
  • Table 172. Germany Angiotensin II Receptor Blocker, by Type USD Million (2022-2027)
  • Table 173. Germany Angiotensin II Receptor Blocker, by Application USD Million (2022-2027)
  • Table 174. Germany Angiotensin II Receptor Blocker, by End Users USD Million (2022-2027)
  • Table 175. France Angiotensin II Receptor Blocker, by Type USD Million (2022-2027)
  • Table 176. France Angiotensin II Receptor Blocker, by Application USD Million (2022-2027)
  • Table 177. France Angiotensin II Receptor Blocker, by End Users USD Million (2022-2027)
  • Table 178. Italy Angiotensin II Receptor Blocker, by Type USD Million (2022-2027)
  • Table 179. Italy Angiotensin II Receptor Blocker, by Application USD Million (2022-2027)
  • Table 180. Italy Angiotensin II Receptor Blocker, by End Users USD Million (2022-2027)
  • Table 181. United Kingdom Angiotensin II Receptor Blocker, by Type USD Million (2022-2027)
  • Table 182. United Kingdom Angiotensin II Receptor Blocker, by Application USD Million (2022-2027)
  • Table 183. United Kingdom Angiotensin II Receptor Blocker, by End Users USD Million (2022-2027)
  • Table 184. Netherlands Angiotensin II Receptor Blocker, by Type USD Million (2022-2027)
  • Table 185. Netherlands Angiotensin II Receptor Blocker, by Application USD Million (2022-2027)
  • Table 186. Netherlands Angiotensin II Receptor Blocker, by End Users USD Million (2022-2027)
  • Table 187. Rest of Europe Angiotensin II Receptor Blocker, by Type USD Million (2022-2027)
  • Table 188. Rest of Europe Angiotensin II Receptor Blocker, by Application USD Million (2022-2027)
  • Table 189. Rest of Europe Angiotensin II Receptor Blocker, by End Users USD Million (2022-2027)
  • Table 190. MEA Angiotensin II Receptor Blocker, by Country USD Million (2022-2027)
  • Table 191. MEA Angiotensin II Receptor Blocker, by Type USD Million (2022-2027)
  • Table 192. MEA Angiotensin II Receptor Blocker, by Application USD Million (2022-2027)
  • Table 193. MEA Angiotensin II Receptor Blocker, by End Users USD Million (2022-2027)
  • Table 194. Middle East Angiotensin II Receptor Blocker, by Type USD Million (2022-2027)
  • Table 195. Middle East Angiotensin II Receptor Blocker, by Application USD Million (2022-2027)
  • Table 196. Middle East Angiotensin II Receptor Blocker, by End Users USD Million (2022-2027)
  • Table 197. Africa Angiotensin II Receptor Blocker, by Type USD Million (2022-2027)
  • Table 198. Africa Angiotensin II Receptor Blocker, by Application USD Million (2022-2027)
  • Table 199. Africa Angiotensin II Receptor Blocker, by End Users USD Million (2022-2027)
  • Table 200. North America Angiotensin II Receptor Blocker, by Country USD Million (2022-2027)
  • Table 201. North America Angiotensin II Receptor Blocker, by Type USD Million (2022-2027)
  • Table 202. North America Angiotensin II Receptor Blocker, by Application USD Million (2022-2027)
  • Table 203. North America Angiotensin II Receptor Blocker, by End Users USD Million (2022-2027)
  • Table 204. United States Angiotensin II Receptor Blocker, by Type USD Million (2022-2027)
  • Table 205. United States Angiotensin II Receptor Blocker, by Application USD Million (2022-2027)
  • Table 206. United States Angiotensin II Receptor Blocker, by End Users USD Million (2022-2027)
  • Table 207. Canada Angiotensin II Receptor Blocker, by Type USD Million (2022-2027)
  • Table 208. Canada Angiotensin II Receptor Blocker, by Application USD Million (2022-2027)
  • Table 209. Canada Angiotensin II Receptor Blocker, by End Users USD Million (2022-2027)
  • Table 210. Mexico Angiotensin II Receptor Blocker, by Type USD Million (2022-2027)
  • Table 211. Mexico Angiotensin II Receptor Blocker, by Application USD Million (2022-2027)
  • Table 212. Mexico Angiotensin II Receptor Blocker, by End Users USD Million (2022-2027)
  • Table 213. Angiotensin II Receptor Blocker: by Type(USD/Units)
  • Table 214. Research Programs/Design for This Report
  • Table 215. Key Data Information from Secondary Sources
  • Table 216. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Angiotensin II Receptor Blocker: by Type USD Million (2016-2021)
  • Figure 5. Global Angiotensin II Receptor Blocker: by Application USD Million (2016-2021)
  • Figure 6. Global Angiotensin II Receptor Blocker: by End Users USD Million (2016-2021)
  • Figure 7. South America Angiotensin II Receptor Blocker Share (%), by Country
  • Figure 8. Asia Pacific Angiotensin II Receptor Blocker Share (%), by Country
  • Figure 9. Europe Angiotensin II Receptor Blocker Share (%), by Country
  • Figure 10. MEA Angiotensin II Receptor Blocker Share (%), by Country
  • Figure 11. North America Angiotensin II Receptor Blocker Share (%), by Country
  • Figure 12. Global Angiotensin II Receptor Blocker: by Type USD/Units (2016-2021)
  • Figure 13. Global Angiotensin II Receptor Blocker share by Players 2021 (%)
  • Figure 14. Global Angiotensin II Receptor Blocker share by Players (Top 3) 2021(%)
  • Figure 15. BCG Matrix for key Companies
  • Figure 16. Daichii Sankyo (Japan) Revenue, Net Income and Gross profit
  • Figure 17. Daichii Sankyo (Japan) Revenue: by Geography 2021
  • Figure 18. Lupin (Germany) Revenue, Net Income and Gross profit
  • Figure 19. Lupin (Germany) Revenue: by Geography 2021
  • Figure 20. Novartis (Switzerland) Revenue, Net Income and Gross profit
  • Figure 21. Novartis (Switzerland) Revenue: by Geography 2021
  • Figure 22. Abbvie (United States) Revenue, Net Income and Gross profit
  • Figure 23. Abbvie (United States) Revenue: by Geography 2021
  • Figure 24. Takeda (Japan) Revenue, Net Income and Gross profit
  • Figure 25. Takeda (Japan) Revenue: by Geography 2021
  • Figure 26. AstraZeneca (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 27. AstraZeneca (United Kingdom) Revenue: by Geography 2021
  • Figure 28. Zydus Cadila (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 29. Zydus Cadila (United Kingdom) Revenue: by Geography 2021
  • Figure 30. Global Angiotensin II Receptor Blocker: by Type USD Million (2022-2027)
  • Figure 31. Global Angiotensin II Receptor Blocker: by Application USD Million (2022-2027)
  • Figure 32. Global Angiotensin II Receptor Blocker: by End Users USD Million (2022-2027)
  • Figure 33. South America Angiotensin II Receptor Blocker Share (%), by Country
  • Figure 34. Asia Pacific Angiotensin II Receptor Blocker Share (%), by Country
  • Figure 35. Europe Angiotensin II Receptor Blocker Share (%), by Country
  • Figure 36. MEA Angiotensin II Receptor Blocker Share (%), by Country
  • Figure 37. North America Angiotensin II Receptor Blocker Share (%), by Country
  • Figure 38. Global Angiotensin II Receptor Blocker: by Type USD/Units (2022-2027)
List of companies from research coverage that are profiled in the study
  • Daichii Sankyo (Japan)
  • Lupin (Germany)
  • Novartis (Switzerland)
  • Abbvie (United States)
  • Takeda (Japan)
  • AstraZeneca (United Kingdom)
  • Zydus Cadila (United Kingdom)
Select User Access Type

Key Highlights of Report


Jul 2022 176 Pages 63 Tables Base Year: 2021 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Angiotensin II Receptor Blocker Market Quantitative research analysis
Global Angiotensin II Receptor Blocker Market Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

The key segments that are playing vital role in Angiotensin II Receptor Blocker Market are by type [Azilsartan, Candesartan, Eprosartan, Irbesartan, Losartan, Olmesartan, Telmisartan and Valsartan], by end use application [Hypertension, Cardiovascular risks, Kidney failure in diabetes and Chronic kidney diseases].
The Angiotensin II Receptor Blocker Market is gaining popularity and expected to see strong valuation by 2027.
  • High Incidence of Target Diseases Such as Obesity, Diabetes and Others
  • Customer Awareness Towards Health Consciousness.

Know More About Global Angiotensin II Receptor Blocker Market Report?

Have a Query? Click Here

Other Related Reports

Ophthalmology PACS Comprehensive Study by Type (Integrated, Standalone), Deployment Mode (On-Premise, Web/Cloud-Based), End-User (Hospitals, Specialty Clinics & Ambulatory Surgery Centers, Research I...
$ 3350
Environmental Disinfection Robots Comprehensive Study by Application (Hospitals, University, Research Institution, Biosafety Laboratory, Others), Control (Fully Automatic, Semi-Automatic), Platform (...
$ 3750
CSSD Autoclave Comprehensive Study by Type (Gravity Displacement Type Autoclave (Vertical Type and Horizontal Type), Positive Pressure Displacement Type Autoclave, Negative Pressure (Vacuum) Displace...
$ 3750
Thumb Braces Comprehensive Study by Type (Splint, Support Strap), Application (Stabilization, Abduction), Distribution Channel (Online, Offline) Players and Region - Global Market Outlook to 2027
$ 3500
Drug Testing System Comprehensive Study by Type (Coca /Cocaine, Cannabis, Amphetamine-Type Stimulants, Opium/Heroin), Application (Diagnosis, Testing, Screening), Sample (Blood, Breathe, Urine, Hair,...
$ 3750
Medical IV Bags Comprehensive Study by Type (Single chamber, Multiple chamber), Application (Dehydration, Pain Medication, Blood Transfusions), Material (PVC, Phthalates, Ethylene Vinyl Acetate, Poly...
$ 3650